{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T16:09:58Z","timestamp":1791389398374,"version":"4.3.3"},"reference-count":42,"publisher":"American Society of Hematology","issue":"2","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,7,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Pharmacologic agents that modulate ubiquitin ligase activity to induce protein degradation are a major new class of therapeutic agents, active in a number of hematologic malignancies. However, we currently have a limited understanding of the determinants of activity of these agents and how resistance develops. We developed and used a novel quantitative, targeted mass spectrometry (MS) assay to determine the relative activities, kinetics, and cell-type specificity of thalidomide and 4 analogs, all but 1 of which are in clinical use or clinical trials for hematologic malignancies. Thalidomide analogs bind the CRL4CRBN ubiquitin ligase and induce degradation of particular proteins, but each of the molecules studied has distinct patterns of substrate specificity that likely underlie the clinical activity and toxicities of each drug. Our results demonstrate that the activity of molecules that induce protein degradation depends on the strength of ligase-substrate interaction in the presence of drug, the levels of the ubiquitin ligase, and the expression level of competing substrates. These findings highlight a novel mechanism of resistance to this class of drugs mediated by competition between substrates for access to a limiting pool of the ubiquitin ligase. We demonstrate that increased expression of a nonessential substrate can lead to decreased degradation of other substrates that are critical for antineoplastic activity of the drug, resulting in drug resistance. These studies provide general rules that govern drug-dependent substrate degradation and key differences between thalidomide analog activity in vitro and in vivo.<\/jats:p>","DOI":"10.1182\/blood.2019000789","type":"journal-article","created":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T23:45:19Z","timestamp":1556754319000},"page":"160-170","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":67,"title":["Patterns of substrate affinity, competition, and degradation kinetics underlie biological activity of thalidomide analogs"],"prefix":"10.1182","volume":"134","author":[{"given":"Adam S.","family":"Sperling","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA;"},{"name":"Division of Hematology, Brigham and Women\u2019s Hospital, Boston, MA;"},{"name":"Broad Institute of MIT and Harvard, Cambridge, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Burgess","sequence":"additional","affiliation":[{"name":"Broad Institute of MIT and Harvard, Cambridge, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hasmik","family":"Keshishian","sequence":"additional","affiliation":[{"name":"Broad Institute of MIT and Harvard, Cambridge, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica A.","family":"Gasser","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA;"},{"name":"Division of Hematology, Brigham and Women\u2019s Hospital, Boston, MA;"},{"name":"Broad Institute of MIT and Harvard, Cambridge, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shruti","family":"Bhatt","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max","family":"Jan","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA;"},{"name":"Division of Hematology, Brigham and Women\u2019s Hospital, Boston, MA;"},{"name":"Broad Institute of MIT and Harvard, Cambridge, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miko\u0142aj","family":"S\u0142abicki","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA;"},{"name":"Division of Hematology, Brigham and Women\u2019s Hospital, Boston, MA;"},{"name":"Broad Institute of MIT and Harvard, Cambridge, MA;"},{"name":"Division of Translational Oncology, National Center for Tumor Diseases Heidelberg, German Cancer Research Center, Heidelberg, Germany; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rob S.","family":"Sellar","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA;"},{"name":"Division of Hematology, Brigham and Women\u2019s Hospital, Boston, MA;"},{"name":"Broad Institute of MIT and Harvard, Cambridge, MA;"},{"name":"Department of Haematology, UCL Cancer Institute, University College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6589-8558","authenticated-orcid":false,"given":"Emma C.","family":"Fink","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA;"},{"name":"Division of Hematology, Brigham and Women\u2019s Hospital, Boston, MA;"},{"name":"Broad Institute of MIT and Harvard, Cambridge, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter G.","family":"Miller","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA;"},{"name":"Division of Hematology, Brigham and Women\u2019s Hospital, Boston, MA;"},{"name":"Broad Institute of MIT and Harvard, Cambridge, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3644-2241","authenticated-orcid":false,"given":"Brian J.","family":"Liddicoat","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA;"},{"name":"Division of Hematology, Brigham and Women\u2019s Hospital, Boston, MA;"},{"name":"Broad Institute of MIT and Harvard, Cambridge, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4875-0022","authenticated-orcid":false,"given":"Quinlan L.","family":"Sievers","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA;"},{"name":"Division of Hematology, Brigham and Women\u2019s Hospital, Boston, MA;"},{"name":"Broad Institute of MIT and Harvard, Cambridge, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohan","family":"Sharma","sequence":"additional","affiliation":[{"name":"Division of Hematology, Brigham and Women\u2019s Hospital, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dylan N.","family":"Adams","sequence":"additional","affiliation":[{"name":"Division of Hematology, Brigham and Women\u2019s Hospital, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elyse A.","family":"Olesinski","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariateresa","family":"Fulciniti","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Namrata D.","family":"Udeshi","sequence":"additional","affiliation":[{"name":"Broad Institute of MIT and Harvard, Cambridge, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6631-1950","authenticated-orcid":false,"given":"Eric","family":"Kuhn","sequence":"additional","affiliation":[{"name":"Broad Institute of MIT and Harvard, Cambridge, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Letai","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikhil C.","family":"Munshi","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven A.","family":"Carr","sequence":"additional","affiliation":[{"name":"Broad Institute of MIT and Harvard, Cambridge, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin L.","family":"Ebert","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA;"},{"name":"Division of Hematology, Brigham and Women\u2019s Hospital, Boston, MA;"},{"name":"Broad Institute of MIT and Harvard, Cambridge, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"21","key":"2020021109231432300_B1","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1182\/blood-2015-07-567958","article-title":"The novel mechanism of lenalidomide activity","volume":"126","author":"Fink","year":"2015","journal-title":"Blood"},{"issue":"6168","key":"2020021109231432300_B2","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1126\/science.1244851","article-title":"Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells","volume":"343","author":"Kr\u00f6nke","year":"2014","journal-title":"Science"},{"issue":"6168","key":"2020021109231432300_B3","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1126\/science.1244917","article-title":"The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins","volume":"343","author":"Lu","year":"2014","journal-title":"Science"},{"issue":"6","key":"2020021109231432300_B4","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1111\/bjh.12708","article-title":"Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4(CRBN.)","volume":"164","author":"Gandhi","year":"2014","journal-title":"Br J Haematol"},{"issue":"7559","key":"2020021109231432300_B5","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/nature14610","article-title":"Lenalidomide induces ubiquitination and degradation of CK1\u03b1 in del(5q) MDS","volume":"523","author":"Kr\u00f6nke","year":"2015","journal-title":"Nature"},{"issue":"6380","key":"2020021109231432300_B6","doi-asserted-by":"crossref","DOI":"10.1126\/science.aao5902","article-title":"Chemically induced proximity in biology and medicine","volume":"359","author":"Stanton","year":"2018","journal-title":"Science"},{"issue":"6","key":"2020021109231432300_B7","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1182\/blood-2015-02-628669","article-title":"CC-122, a pleiotropic pathway modifier, mimics an interferon response and has antitumor activity in DLBCL","volume":"126","author":"Hagner","year":"2015","journal-title":"Blood"},{"issue":"7611","key":"2020021109231432300_B8","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nature18611","article-title":"A novel cereblon modulator recruits GSPT1 to the CRL4(CRBN) ubiquitin ligase","volume":"535","author":"Matyskiela","year":"2016","journal-title":"Nature"},{"issue":"10","key":"2020021109231432300_B9","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1136\/annrheumdis-2017-212916","article-title":"Cereblon modulator iberdomide induces degradation of the transcription factors Ikaros and Aiolos: immunomodulation in healthy volunteers and relevance to systemic lupus erythematosus","volume":"77","author":"Schafer","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"6414","key":"2020021109231432300_B10","doi-asserted-by":"crossref","DOI":"10.1126\/science.aat0572","article-title":"Defining the human C2H2 zinc finger degrome targeted by thalidomide analogs through CRBN","volume":"362","author":"Sievers","year":"2018","journal-title":"Science"},{"issue":"8","key":"2020021109231432300_B11","doi-asserted-by":"crossref","first-page":"e368","DOI":"10.3324\/haematol.2017.186601","article-title":"Cereblon loss and up-regulation of c-Myc are associated with lenalidomide resistance in multiple myeloma patients","volume":"103","author":"Franssen","year":"2018","journal-title":"Haematologica"},{"issue":"5","key":"2020021109231432300_B12","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1111\/bjh.12338","article-title":"High expression of cereblon (CRBN) is associated with improved clinical response in patients with multiple myeloma treated with lenalidomide and dexamethasone","volume":"161","author":"Heintel","year":"2013","journal-title":"Br J Haematol"},{"issue":"8","key":"2020021109231432300_B13","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1007\/s00277-014-2063-7","article-title":"Expression of cereblon protein assessed by immunohistochemicalstaining in myeloma cells is associated with superior response of thalidomide- and lenalidomide-based treatment, but not bortezomib-based treatment, in patients with multiple myeloma","volume":"93","author":"Huang","year":"2014","journal-title":"Ann Hematol"},{"issue":"1","key":"2020021109231432300_B14","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/nmeth.2309","article-title":"Quantitative analysis of peptides and proteins in biomedicine by targeted mass spectrometry","volume":"10","author":"Gillette","year":"2013","journal-title":"Nat Methods"},{"issue":"15","key":"2020021109231432300_B15","doi-asserted-by":"crossref","first-page":"7548","DOI":"10.1021\/acs.analchem.6b00946","article-title":"Automated microchromatography enables multiplexing of immunoaffinity enrichment of peptides to greater than 150 for targeted MS-Based Assays","volume":"88","author":"Ippoliti","year":"2016","journal-title":"Anal Chem"},{"issue":"6","key":"2020021109231432300_B16","doi-asserted-by":"crossref","first-page":"M111.013854","DOI":"10.1074\/mcp.M111.013854","article-title":"Interlaboratory evaluation of automated, multiplexed peptide immunoaffinity enrichment coupled to multiple reaction monitoring mass spectrometry for quantifying proteins in plasma","volume":"11","author":"Kuhn","year":"2012","journal-title":"Mol Cell Proteomics"},{"issue":"4","key":"2020021109231432300_B17","doi-asserted-by":"crossref","first-page":"M110.005645","DOI":"10.1074\/mcp.M110.005645","article-title":"Evaluation of large scale quantitative proteomic assay development using peptide affinity-based mass spectrometry","volume":"10","author":"Whiteaker","year":"2011","journal-title":"Mol Cell Proteomics"},{"key":"2020021109231432300_B18","doi-asserted-by":"crossref","first-page":"15398","DOI":"10.1038\/ncomms15398","article-title":"pSILAC mass spectrometry reveals ZFP91 as IMiD-dependent substrate of the CRL4CRBN ubiquitin ligase","volume":"8","author":"An","year":"2017","journal-title":"Nat Commun"},{"key":"2020021109231432300_B19","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.38430","article-title":"Thalidomide promotes degradation of SALL4, a transcription factor implicated in Duane Radial Ray syndrome","volume":"7","author":"Donovan","year":"2018","journal-title":"eLife"},{"issue":"11","key":"2020021109231432300_B20","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1038\/leu.2010.190","article-title":"Pomalidomide (CC4047) plus low dose dexamethasone (Pom\/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM)","volume":"24","author":"Lacy","year":"2010","journal-title":"Leukemia"},{"issue":"5","key":"2020021109231432300_B21","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/j.cell.2015.01.042","article-title":"Drug-induced death signaling strategy rapidly predicts cancer response to chemotherapy","volume":"160","author":"Montero","year":"2015","journal-title":"Cell"},{"issue":"8","key":"2020021109231432300_B22","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1021\/acschembio.5b00143","article-title":"NanoBRET\u2013a novel BRET platform for the analysis of protein-protein interactions","volume":"10","author":"Machleidt","year":"2015","journal-title":"ACS Chem Biol"},{"issue":"18","key":"2020021109231432300_B23","doi-asserted-by":"crossref","first-page":"4771","DOI":"10.1182\/blood-2011-05-356063","article-title":"Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide","volume":"118","author":"Zhu","year":"2011","journal-title":"Blood"},{"issue":"6","key":"2020021109231432300_B24","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1111\/ejh.12192","article-title":"Responsiveness of cytogenetically discrete human myeloma cell lines to lenalidomide: lack of correlation with cereblon and interferon regulatory factor 4 expression levels","volume":"91","author":"Greenberg","year":"2013","journal-title":"Eur J Haematol"},{"issue":"1","key":"2020021109231432300_B25","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.leukres.2013.08.015","article-title":"The clinical significance of cereblon expression in multiple myeloma","volume":"38","author":"Schuster","year":"2014","journal-title":"Leuk Res"},{"issue":"2","key":"2020021109231432300_B26","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1111\/bjh.12622","article-title":"Measuring cereblon as a biomarker of response or resistance to lenalidomide and pomalidomide requires use of standardized reagents and understanding of gene complexity","volume":"164","author":"Gandhi","year":"2014","journal-title":"Br J Haematol"},{"issue":"1","key":"2020021109231432300_B27","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1038\/s41375-018-0205-y","article-title":"A genome-scale CRISPR-Cas9 screening in myeloma cells identifies regulators of immunomodulatory drug sensitivity","volume":"33","author":"Liu","year":"2019","journal-title":"Leukemia"},{"issue":"12","key":"2020021109231432300_B28","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1182\/blood-2018-01-821769","article-title":"Genome-wide screen identifies cullin-RING ligase machinery required for lenalidomide-dependent CRL4CRBN activity","volume":"132","author":"Sievers","year":"2018","journal-title":"Blood"},{"issue":"5","key":"2020021109231432300_B29","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/j.cell.2011.10.035","article-title":"The molecular basis of CRL4DDB2\/CSA ubiquitin ligase architecture, targeting, and activation","volume":"147","author":"Fischer","year":"2011","journal-title":"Cell"},{"issue":"2","key":"2020021109231432300_B30","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/nbt.3437","article-title":"Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9","volume":"34","author":"Doench","year":"2016","journal-title":"Nat Biotechnol"},{"issue":"12","key":"2020021109231432300_B31","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1038\/ng.3984","article-title":"Computational correction of copy number effect improves specificity of CRISPR-Cas9 essentiality screens in cancer cells","volume":"49","author":"Meyers","year":"2017","journal-title":"Nat Genet"},{"issue":"10","key":"2020021109231432300_B32","doi-asserted-by":"crossref","first-page":"e354","DOI":"10.1038\/bcj.2015.66","article-title":"Rate of CRL4(CRBN) substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4","volume":"5","author":"Bjorklund","year":"2015","journal-title":"Blood Cancer J"},{"issue":"14","key":"2020021109231432300_B33","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1056\/NEJMoa061292","article-title":"Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion","volume":"355","author":"List","year":"2006","journal-title":"N Engl J Med"},{"issue":"7597","key":"2020021109231432300_B34","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/nature16979","article-title":"Structural basis of lenalidomide-induced CK1\u03b1 degradation by the CRL4(CRBN) ubiquitin ligase","volume":"532","author":"Petzold","year":"2016","journal-title":"Nature"},{"issue":"7580","key":"2020021109231432300_B35","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/nature15736","article-title":"Pharmacogenomic agreement between two cancer cell line data sets","volume":"528","author":"Cancer Cell Line Encyclopedia","year":"2015","journal-title":"Nature"},{"issue":"1","key":"2020021109231432300_B36","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/ejh.12457","article-title":"High level of full-length cereblon mRNA in lower risk myelodysplastic syndrome with isolated 5q deletion is implicated in the efficacy of lenalidomide","volume":"95","author":"Jonasova","year":"2015","journal-title":"Eur J Haematol"},{"issue":"1","key":"2020021109231432300_B37","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1080\/10428194.2018.1466290","article-title":"Expression of CRBN, IKZF1, and IKZF3 does not predict lenalidomide sensitivity and mutations in the cereblon pathway are infrequent in multiple myeloma","volume":"60","author":"Dimopoulos","year":"2019","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"2020021109231432300_B38","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1038\/leu.2016.384","article-title":"IKZF1 expression is a prognostic marker in newly diagnosed standard-risk multiple myeloma treated with lenalidomide and intensive chemotherapy: a study of the German Myeloma Study Group (DSMM)","volume":"31","author":"Kr\u00f6nke","year":"2017","journal-title":"Leukemia"},{"issue":"1","key":"2020021109231432300_B39","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/s13045-016-0354-2","article-title":"High IKZF1\/3 protein expression is a favorable prognostic factor for survival of relapsed\/refractory multiple myeloma patients treated with lenalidomide","volume":"9","author":"Pourabdollah","year":"2016","journal-title":"J Hematol Oncol"},{"issue":"4","key":"2020021109231432300_B40","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1182\/blood-2014-02-557819","article-title":"Identification of cereblon-binding proteins and relationship with response and survival after IMiDs in multiple myeloma","volume":"124","author":"Zhu","year":"2014","journal-title":"Blood"},{"issue":"6241","key":"2020021109231432300_B41","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1126\/science.aab1433","article-title":"Drug development. Phthalimide conjugation as a strategy for in vivo target protein degradation","volume":"348","author":"Winter","year":"2015","journal-title":"Science"},{"issue":"6336","key":"2020021109231432300_B42","article-title":"Anticancer sulfonamides target splicing by inducing RBM39 degradation via recruitment to DCAF15 [published correction appears in Science. 2017;356(6340)]","volume":"356","author":"Han","year":"2017","journal-title":"Science"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/134\/2\/160\/1553917\/bloodbld2019000789.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/134\/2\/160\/1553917\/bloodbld2019000789.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,11]],"date-time":"2020-02-11T10:02:45Z","timestamp":1581415365000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/134\/2\/160\/260688\/Patterns-of-substrate-affinity-competition-and"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,11]]},"references-count":42,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,7,11]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2019000789","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.735679748.793563709","asserted-by":"object"}]},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,11]]}}}